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does not parallel to cognitive changes in Alzheimer’s disease (AD) and cognitively normal (CN) sub-
jects across different studies. Therefore, identifying novel proteins to characterize symptomatic AD
samples is important.
Methods: Proteins were profiled using a multianalyte platform by Rules Based Medicine (MAP-
RBM). Due to underlying heterogeneity and unbalanced sample size, we combined subjects (344
AD and 325 CN) from three cohorts: Alzheimer’s Disease Neuroimaging Initiative, Penn Center
for Neurodegenerative Disease Research of the University of Pennsylvania, and Knight Alzheimer’s
Disease Research Center at Washington University in St. Louis. We focused on samples whose cogni-
tive and amyloid status was consistent. We performed linear regression (accounted for age, gender,
number of apolipoprotein E (APOE) e4 alleles, and cohort variable) to identify amyloid-related pro-
teins for symptomatic AD subjects in this largest ever CSF–based MAP-RBM study. ANOVA and
Tukey’s test were used to evaluate if these proteins were related to cognitive impairment changes
as measured by mini-mental state examination (MMSE).
Results: Seven proteins were significantly associated with Ab1–42 levels in the combined cohort
(false discovery rate adjusted P , .05), of which lipoprotein a (Lp(a)), prolactin (PRL), resistin,
and vascular endothelial growth factor (VEGF) have consistent direction of associations across
every individual cohort. VEGF was strongly associated with MMSE scores, followed by pancreatic
polypeptide and immunoglobulin A (IgA), suggesting they may be related to staging of AD.
Discussion: Lp(a), PRL, IgA, and tissue factor/thromboplastin have never been reported for AD
diagnosis in previous individual CSF–based MAP-RBM studies. Although some of our reported
analytes are related to AD pathophysiology, other’s roles in symptomatic AD samples worth further
explorations.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is
an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: Cerebrospinal fluid; Biomarkers; Alzheimer’s disease; Cognitive impairment; Amyloid beta; Dementia1. Introduction
Alzheimer’s disease (AD) is pathologically characterized
by the presence of extracellular amyloid plaques (APs) and
intracellular hyperphosphorylated tau neurofibrillary tan-
gles, which are known to be correlated with cerebrospinal
fluid (CSF) levels of amyloid b (Ab1–42), total tau (t-tau),
and phosphorylated tau (p-tau181) [1,2]. The measurements
of these proteins in the CSF using enzyme-linked immuno-
sorbent assay (ELISA) and xMAP technology were able to
distinguish most AD and cognitively normal (CN) subjects
[3,4]. These CSF biomarkers are included in the revised
version of the commonly used diagnosis criteria Institute of
Neurological and Communicative Disorders and Stroke
(NINCDS) and the Alzheimer’s Disease and Related
Disorders Association (ADRDA) in 2011 for supporting
clinical diagnoses [5]. Analyses of CSF Ab1–42, t-tau, and
p-tau181 in a meta-analysis study (combining 11 different
studies) were shown to accurately classify AD patients
(area under the curve, 0.86) [6]. Nevertheless, CSF Ab1–42
reaches pathologic values and then plateau during the pre-
clinical phase of the disease, when subjects still have normal
cognition, and therefore show low correlation with cognitive
symptoms [7]. Although CSF t-tau levels show a better cor-
relation with cognition, there is a need for additional CSF
biomarkers that track cognitive changes closely. Due to the
heterogeneity of the disease populations, it is critical to vali-
date identified biomarker candidates across different cohorts.Recent studies have been conducted to identify and char-
acterize other potential CSF biomarkers, as reviewed by Fa-
gan and Perrin [8]. These include visinin-like protein-1 and
chitinase 3-like 1 (cartilage glycoprotein-39; YKL-40) for
which follow-up studies explored their roles in different dis-
ease populations [9–11]. However, disappointingly, most of
the other candidate biomarkers have not been replicated to
date. Comparing to Ab1–42 and t-tau, they possibly
participate in different time frames in the AD spectrum
[12,13]. Therefore, by combining cohorts comprised
subjects with different levels of cognitive deficits, we
postulate that the candidate biomarkers may better explain
the disease progression in a heterogeneous population
defined by cognitive measures such as mini-mental state ex-
amination (MMSE) as opposed to more global clinical status
(AD vs. CN).
Multiplex methods can identify CSF biomarkers altered
in AD and have utility as potential diagnostic and disease
staging tools, and for nominating novel drug targets and
tracking treatment responses for investigational interven-
tions. Hu et al. [14] previously conducted a study on subjects
from the University of Pennsylvania (UPenn) using the Hu-
man DiscoveryMAP panel from Rules Based Medicine
(MAP-RBM), where they identified CSF biomarkers
(including thirteen analytes from the MAP-RBM) for distin-
guishing pathologically confirmed AD from CN subjects.
Another study involved subjects recruited at Knight Alz-
heimer’s Disease Research Center at Washington University
Y.Y. Leung et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 339-348 341in St. Louis (WUSTL), in which biomarkers were identified
to distinguish very mild and mild AD from CN subjects [15].
In a recent study on subjects from Alzheimer’s Disease Neu-
roimaging Initiative (ADNI) [16], Mattsson et al. focused on
46 healthy control subjects and showed that some proteins
from the MAP-RBM panel can predict future Ab1–42 reduc-
tion in subjects with normal baseline Ab1–42, suggesting they
can pathologically predict future development of the brain
APs at the earliest stages of AD, before their widespread
development.
Although all studies described used the same MAP-RBM
panel, results could not be directly comparable for two rea-
sons. First, each study compared a specific stage of AD sam-
ples (pathologically confirmed AD in UPenn, mild AD in
WUSTL) to CN. Second, their preprocessing steps were
different—only ADNI data were log-transformed. Driven
by this, we believe it would be of great value to create a
new cohort by combining all these MAP-RBM data from
all cohorts (ADNI—a clinical trial type cohort, UPenn—a
tertiary care memory center, and WUSTL—a community-
dwelling research cohort). These data thus contain subjects
of different levels of cognitive deficits. Given such a hetero-
geneous population, the novelty in our study lies in identi-
fying candidate biomarkers that may better explain the
disease progression instead of diagnosis. The purpose of
our study was twofold: (1) to identify MAP-RBM analytes
suggestive of the presence or absence of amyloid pathology
quantified by CSF Ab1–42 levels (Ab1–42 cutoff defined by
Shaw et al. [17] regardless of clinical diagnoses) and (2)
study how these biomarkers correlate with cognitive perfor-
mance. Despite our different study focus thus limiting our
choice of subjects from each individual studies [14–16],
we have the largest sample size so far for MAP-RBM study
in AD. Also our data have more similar numbers of symp-
tomatic cases and CN controls as compared with individual
studies. To summarize our multicenter study, we first applied
same preprocessing steps including imputation for low
values, excluding outliers and normalization for MAP-
RBM on all cohorts. Because there are cohort-specific de-
mographics, we merged all cohorts together, adjusted for
age, gender, and number of APOE ε4 alleles, and used the
cohort indicator as an additional covariate to control for
batch effects. We first calculated the correlation of these an-
alytes with Ab1–42 levels, then evaluated their utility to
differentiate subjects with different cognitive problems.2. Materials and methods
2.1. Participants, biomarker collection, and analysis tools
Part of the data used in the preparation of this article
were obtained from the ADNI database (adni.loni.ucla.
edu). The ADNI was launched in 2003 by the National
Institute on Aging, the National Institute of Biomedical
Imaging and Bioengineering, the Food and Drug Admin-
istration, private pharmaceutical companies and nonprofitorganizations, as a $60 million, 5-year public-private part-
nership. The primary goal of ADNI has been to test
whether serial magnetic resonance imaging, positron
emission tomography, other biological markers, and clin-
ical and neuropsychological assessment can be combined
to measure the progression of mild cognitive impairment
(MCI) and early AD. Determination of sensitive and spe-
cific markers of very early AD progression is intended to
aid researchers and clinicians to develop new treatments
and monitor their effectiveness, as well as lessen the
time and cost of clinical trials.
In ADNI, baseline CSF samples were obtained in the
morning after an overnight fasting and processed as previ-
ously described [17–19]. In brief, lumbar puncture (LP)
was performed via aspiration with a 20- or 24-gauge spinal
needle as described in the ADNI procedures manual (http://
www.adni-info.org/). CSF was collected into polypro-
pylene collection tubes or syringes provided to each site,
then transferred into polypropylene transfer tubes without
any centrifugation step, followed by freezing on dry ice
within 1 hour after collection, and shipped overnight to
the ADNI Biomarker Core laboratory at the University of
Pennsylvania Medical Center on dry ice. Aliquots
(0.5 mL) were prepared from these samples after thawing
(1 hour) at room temperature and gentle mixing. The
aliquots were stored in bar code–labeled polypropylene
vials at 280C.
Patients and control subjects were recruited and longitu-
dinally followed at UPenn in specialty services dedicated to
the evaluation and management of neurodegenerative dis-
eases [14]. All protocols were approved by the Penn Institu-
tional Review Board. Subjects were evaluated at the time of
CSF collection, following the similar standard operating
procedures as those in ADNI. Biofluid samples were
collected up to 3:00 PM during working hours after at least
a 4-hour fast. Similarly, LP was performed with a 20- or 24-
gauge spinal needle, and CSF was collected via gravity drip
or suction method using clear polypropylene tubes and
aliquoted into 0.5 mL in 1.5-mL cryogenic tubes after
collection without a centrifugation step. Aliquoted samples
were sent in sealed containers on dry ice for storage in
280C in freezers specifically dedicated to banking human
biofluid samples.
At WUSTL, participants were volunteers enrolled in lon-
gitudinal studies of healthy aging and dementia at the Knight
Alzheimer’s Disease Research Center [20]. The presence or
absence of dementia (and, when present, its severity) was
operationalized with the clinical dementia rating (CDR) in
accordance with standard protocols and criteria [21]. A
CDR of 0 indicates cognitive normality, whereas CDRs of
0.5, 1, 2, and 3 are indicative of very mild, mild, moderate,
and severe dementia, respectively. For individuals who are
CDR .0, the diagnosis of symptomatic AD is based on
NINCDS-ADRDA criteria [22]. Volumes of 25–30 mL of
CSF were collected by LP via gravity drip at 8:00 AM after
overnight fasting in polypropylene tubes as previously
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gradient effects, briefly centrifuged at low speed to pellet
any cellular elements, and aliquoted (500 mL) into polypro-
pylene tubes before freezing at 284 C. For all biomarker
measures, samples were continuously kept on ice, and assays
were performed on sample aliquots after a single thaw after
initial freezing.
After the samples were collected, they were shipped to
Rules Based Medicine (Austin, TX) and evaluated using
the MAP-RBM platform, a quantitative multiplexed immu-
noassay based on Luminex xMAP technology [24,25]. For
ADNI and UPenn cohorts, Ab1–42 levels were measured
using xMAP Luminex platform (Luminex Corp, Austin,
TX) with Fujirebio (formerly Innogenetics, Ghent,
Belgium) immunoassay bead-based kits (INNO-BIA Alz-
Bio3) [17]. According to the manufacturer, AlzBio3
intra-assay variability is ,4%, inter-assay variability is
,10% [26], and lower limit of quantification is 20–50
pg/mL for Ab1–42 [27]. For the WUSTL cohort, samples
were measured using quantitative ELISA with Fujirebio
(formerly Innogenetics) immunoassay plate-based kits (IN-
NOTEST) [15]. Because Ab1–42 proteins were not
measured using the same assay across the cohorts, and
the assays are known to provide different absolute levels
(although positively correlated) [3], we used the following
formulas to convert WUSTL ELISA levels to their corre-
sponding Luminex estimates: Luminex Ab1–42 5
83.72 1 0.15 ! ELISA Ab1–42.
APOE genotyping was done similarly across cohorts us-
ing DNA from EDTA blood samples: TaqMan allelic
discrimination assays were used for nucleotides 334 T/C
(rs 429358) and 472 C/T (rs 7412) using a real-time thermo-
cycler (ABI 7500 or 7900; Life Technologies), as previously
described [28,29].Table 1
Demographic of subjects included in CSF MAP-RBM from all three cohorts in o
clinical diagnosis labels)
Demographic ADNI UPenn
Diagnosis AD CN AD
n (subjects) 64 58 225
Gender (F%) 45 52 59
Age, y (SD) 74 (8) 75 (5) 72 (9)
APOE ε4 alleles, %
0 48 59 35
1 36 33 51
2 16 8 14
MMSE score at baseline (SD) 23 (2) 29 (1) 21 (6)
MMSE groups, %
0–10 0 0 5
11–20 6 0 27
21–25 78 1 35
26–28 16 16 22
29–30 0 83 2
Abbreviations: CSF, cerebrospinal fluid; MAP-RBM, multianalyte platform by R
roimaging Initiative; UPenn, University of Pennsylvania; WUSTL, Washington
MMSE, mini-mental state examination score; SD, standard deviation.MAP-RBM data from 160 ADNI subjects, 275 UPenn
subjects, and 267 WUSTL subjects were available
(Supplementary Table 1) [14–16]. We removed subjects
whose Ab1–42 levels disagree with their clinical diagnoses,
e.g. AD subjects with Ab1–42 levels (Ab1–42. 192 pg/mL)
similar to CN (5, 25, and 3 in ADNI, UPenn, and
WUSTL) and normal subjects with low Ab1–42 levels
(Ab1–42 ,192 pg/mL) typical for AD (33, 3, and 135 in
ADNI, UPenn, and WUSTL). This resulted in 122 ADNI
subjects, 247 UPenn subjects, and 129 WUSTL subjects
(Table 1). The demographics of these cohorts are different
as follows: (1) UPenn contains more AD than controls,
and the subjects are younger. (2) Gender ratio of ADNI is
different from the others. (3) AD subjects in UPenn and
WUSTL possess a wider range of cognitive deficit problems.
To study different levels of cognitive impairments, we
used MMSE nearest to the time of LP to divide subjects
into five stages/groups of cognitive impairment [30]:
29–30 (CN), 26–28 (questionable), 21–25 (mild), 11–20
(moderate), and 0–10 (severe dementia).
2.2. Preprocessing MAP-RBM data
As each analyte was analyzed by a specific immunoassay
in MAP-RBM and therefore may follow different statistical
distributions, special preprocessing steps are required before
the analysis. In earlier studies, we identified various ways of
preprocessing the MAP-RBM data [14–16]. To compare the
data across three cohorts systematically, we standardized the
preprocessing steps as follows:
1. Processing of analytes with missing and low values:
Analytes with 10% or more missing or low (“LOW”,
defined by the original file obtained from MAP-
RBM) values were excluded. For the remainingur study (after removing subjects with disagreement of Ab1–42 levels and
WUSTL Combined
CN AD CN AD CN
22 56 73 345 153
68 63 62 57 58
70 (11) 77 (7) 70 (7) 73 (8) 72 (8)
77 27 85 36 74
23 63 15 50 23
0 10 0 14 3
29 (1) 24 (3) 29 (1) 22 (5) 29 (1)
0 0 0 3 0
0 18 0 21 0
0 45 0 45 1
14 33 27 23 21
86 4 73 2 78
ules Based Medicine; Ab1–42, amyloid b; ADNI, Alzheimer’s Disease Neu-
University in St. Louis; AD, Alzheimer’s disease; CN, cognitive normal;
Table 2
Analytes significantly associated with CSF Ab1–42 levels (FDR adjusted
P, .05) from univariate linear regression analyses in each individual cohort
and in the combined cohort
MAP-
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ing a value of half of the least detectable dose (LDD)
value. The LDD represents the concentration of the
analyte that produces a signal above the background
level with 99% confidence, which is considered as
the most reliable smallest measurement for the protein
assays used.
2. Exclusion of outliers: We excluded outliers that were
outside five standard deviations from the overall
mean.
3. Logarithmic transformation: In ADNI, all analytes not
normally distributed were log-10 transformed. In UP-
enn andWUSTL, a two-step approach was performed.
If analytes were also present in ADNI, they were trans-
formed in the same way as in ADNI. If not, they were
log-10 transformed if they had a right-skewed distri-
bution. Transforming each analyte to the same distri-
bution across cohorts was essential to ensure proper
comparison of these analytes across different cohorts.
A main objective of this study was to identify robust sig-
nals that are supported by multiple cohorts despite the het-
erogeneity of samples. After quality control, 52 analytes
were still available across all three cohorts and were retained
for analysis (Supplementary Table 2).
2.3. Statistical analysis
All analyses were performed using R version 2.14.1 (R
Foundation for Statistical Computing). Ab1–42 was not on
the MAP-RBM panel and was log-10 transformed such
that normality assumptions are satisfied. Univariate analyses
of these analytes were tested using linear regression models,
adjusting for age at LP, gender, and the number of APOE ε4
alleles. In the combined analysis, we used the cohort indica-
tor as an additional covariate to control for batch effects.
Analysis of covariance (ANOVA) was conducted on
MMSE scores between groups, and Tukey’s test was used
to assess the statistical significance [31]. Effect sizes were
calculated using Cohen’s d [32]. All statistical tests were
two sided.RBM
analyte ADNI UPenn WUSTL Combined
VEGF 0.067 (20.56) 0.009 (20.46) 0.000 (20.91) 0.000 (20.48)
FABP 0.007 (0.79) 0.013 (0.98) 0.554 (20.03) 0.000 (0.43)
RETN 0.771 (0.34) 0.000 (0.55) 0.860 (0.22) 0.000 (0.28)
CD40A 0.106 (20.49) 0.119 (0.13) 0.118 (20.37) 0.000 (20.19)
PRL 0.115 (0.42) 0.119 (0.46) 0.935 (0.23) 0.005 (0.27)
Lp(a) 0.739 (0.20) 0.051 (0.43) 0.735 (0.08) 0.012 (0.18)
HGF 0.023 (0.55) 0.286 (0.55) 0.935 (20.01) 0.013 (0.29)
Abbreviations: CSF, cerebrospinal fluid; Ab1–42, amyloid b; FDR, false
discovery rate; MAP-RBM, multianalyte platform by Rules Based Medi-
cine; ADNI, Alzheimer’s Disease Neuroimaging Initiative; UPenn, Univer-
sity of Pennsylvania; WUSTL, Washington University in St. Louis; VEGF,
vascular endothelial growth factor; FABP, fatty acid binding protein; RETN,
resistin; CD40A, CD40 antigen; PRL, prolactin; Lp(a), lipoprotein a;
HGF, hepatocyte growth factor.
NOTE. Effect sizes were shown in parenthesis. Bold text indicates
P , .05.3. Results
We analyzed MAP-RBM data from the three cohorts to
find analytes that were associated with CSF Ab1–42 levels
in individuals whose cognitive status was consistent with
their amyloid status as defined by CSF Ab1–42 levels
(asymptomatic/high Ab1–42 vs. symptomatic/low Ab1–42).
First, levels for each analyte were adjusted for age, gender,
and number of APOE ε4 alleles using ANCOVA
(Supplementary Table 3). We observed that the number
of APOE ε4 alleles had the largest effects on the MAP-
RBM analytes in WUSTL, followed by UPenn. The effect
of age was significant only in WUSTL. The effect of
gender was not significant at all. Given the cohort-
specific differences, we included all these covariates inour subsequent models. We performed regression analysis
on three cohorts separately, then analyzed the combined
data set as described.3.1. MAP-RBM analytes correlated with CSFAb1–42
levels in individual and combined cohorts
We first performed linear regression to find which
MAP-RBM analytes correlated with CSF Ab1–42 levels.
Analytes with false discovery rate (FDR) adjusted
P , .05 (bold text) in at least one cohort are summarized
in Table 2 (effect sizes in parenthesis). Complete results
are in Supplementary Table 4. We observed that vascular
endothelial growth factor (VEGF) and fatty acid binding
protein (FABP) were the most significantly associated an-
alytes in three of four analyses, followed by resistin
(RETN), which was identified in UPenn and the combined
cohort. VEGF, RETN, prolactin (PRL), and lipoprotein a
(Lp(a)) have consistent direction of associations across
cohorts, as indicated by the sign (positive or negative)
of effect sizes, although associations of PRL and Lp(a)
were only significant when the three cohorts were
combined.
The distributions of CSF VEGF and RETN levels are
shown in Fig. 1. We observed the direction of the changes
associated with diagnosis was consistent across all cohorts,
suggesting their robustness. The association between
VEGF and CSFAb1–42 levels was stronger in the symptom-
atic versus nonsymptomatic group, yet the effect was oppo-
site for that of RETN (results not shown). Boxplots of other
candidate MAP-RBM analytes, FABP, CD40 antigen
(CD40A), PRL, Lp(a) and hepatocyte growth factor
(HGF), are in Supplementary Fig. 1.
Fig. 1. Distributions ofMAP-RBManalytes that were found to bemostly associated with CSFAb1–42 levels fromTable 2: (A) VEGF and (B) RETN. Significant
codes: **P , .01, ***P , .001. Abbreviations: MAP-RBM, multianalyte platform by Rules Based Medicine; CSF, cerebrospinal fluid; Ab1–42, amyloid b;
VEGF, vascular endothelial growth factor; RETN, resistin; ADNI, Alzheimer’s Disease Neuroimaging Initiative; UPenn, University of Pennsylvania; WUSTL,
Washington University in St. Louis.
Table 3
FDR adjusted P values obtained from ANOVAmodels on comparing means
of analytes across different MMSE groups
ADNI UPenn WUSTL Combined
VEGF 0.994 0.003 0.244 0.001
PPP 0.994 0.014 0.244 0.004
Lp(a) 0.994 0.014 0.874 0.016
IgA 0.994 0.044 0.244 0.017
TF 0.994 0.014 0.988 0.044
Abbreviations: FDR, false discovery rate; ANOVA, analysis of variance;
MMSE,mini-mental state examination; ADNI, Alzheimer’s Disease Neuro-
imaging Initiative; UPenn, University of Pennsylvania; WUSTL, Washing-
ton University in St. Louis; VEGF, vascular endothelial growth factor; IgA,
immunoglobulin A; LPA, lipoprotein a.
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severity of cognitive impairment
We examined if MAP-RBM analytes were associated
levels of cognitive impairment. We focused on subjects
that had low Ab1–42 levels (Ab1–42 ,192 pg/mL) and
MMSE 28 and divided them into four groups by
MMSE scores (groups “GP26–28” of MMSE 5 26–28,
“GP21–25” of MMSE 5 21–25, “GP11–20” of
MMSE 5 11–20, and “GP0–10” of MMSE 5 0–10). We
performed ANOVA to identify analytes that differ among
groups. Table 3 summarizes the analytes of which their
FDR adjusted P values were ,.05 in the combined cohort.
Three new analytes not found in Table 2 were pancreatic
polypeptide (PPP), immunoglobulin A (IgA) and tissue
factor/thromboplastin (TF).
Fig. 2. Distributions of VEGF across MMSE groups in the combined
cohort. Groups “GP26–28”: MMSE 5 26–28; “GP21–25”: MMSE 5 21–
25; “GP11–20”: MMSE 5 11–20; and “GP0–10”: MMSE5 0–10. Abbre-
viations: VEGF, vascular endothelial growth factor; MMSE, mini-mental
state examination.
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Fig. 2 and others in Supplementary Fig. 2. VEGF showed
significant differences across certain MMSE groups in UP-
enn and the combined cohort. As cognitive impairment
became worse, CSF level of VEGF decreased. To determine
if the differences acrossMMSE groups were statistically sig-
nificant, Tukey’s test was performed on the combined
cohort. At the 95% confidence interval, the group difference
between “GP11–20” and “GP0–10” was the most significant
(P 5 .014). Other analytes having significant group differ-
ences include (1) PPP, “GP26–28” and “GP21–25”
(P 5 .007) and (2) IgA, “GP11–20” and “GP0–10”
(P 5 .031).4. Discussion
After adjusting for confounding cohort and demo-
graphic effects, this study demonstrates that robust protein
analytes measured by the MAP-RBM platform can be
identified in CSF. Seven analytes (CD40A, FABP, HGF,
Lp(a), PRL, RETN, and VEGF [Table 2]) showed signifi-
cant correlations with CSF Ab1–42 levels in the combined
cohort. Four of them (Lp(a), PRL, RETN, and VEGF)
showed consistent direction of associations across all indi-
vidual cohorts as indicated by the effect sizes. We also
found that VEGF was most significantly associated with
MMSE in the combined cohort, followed by PPP, Lp(a),
IgA, and TF.
We did not include CN subjects with abnormal CSF
Ab1–42 levels in the analysis as our goal was to identifyMAP-RBM analytes that correlate with amyloid pathol-
ogy. However, it is still of our interest to explore the char-
acteristics of analytes in Table 2 for this group. We
included back the 171 samples in this current analyses.
Two analytes, PRL and VEGF remained significant
(FDR P , .05) and had smaller effect sizes (same direc-
tion) across cohorts, suggesting the identified biomarkers
were comparatively less effective in the nonsymptomatic
population.
The identified top 10 analytes from our analysis are asso-
ciated with different aspects of AD physiopathology. Lp(a),
PRL, IgA, and TF have never been reported in previous in-
dividual studies using the CSF MAP-RBM panel [14–16].
CD40A is responsible for regulating immune response
and is widely expressed in the brain [33]. It is also involved
in microglial activation and brain inflammation in AD [34].
High baseline CD40A levels predicted reduced Ab1–42
levels over time in ADNI [16], but this analyte was not re-
ported in the other two studies [14,15]. We also observed
high CD40A levels in subjects with high Ab1–42 levels
(Supplementary Fig. 1B).
FABP may contribute to neurodegeneration via intracra-
nial lipid metabolism [35]. It has been studied in CSF and
serum in AD [36] and was also reported from both UPenn
and WUSTL studies [14,15]. The reported higher FABP
levels in dementia subjects, as well as in early phases of
AD [37], are consistent with our findings that FABP levels
are higher in AD subjects in all cohorts (Supplementary
Fig. 1A).
HGF is a potent mitogen for mature hepatocytes. It is ex-
pressed in astrocytes and is associated with white matter
changes [38]. In WUSTL, AD subjects had slightly higher
HGF levels in CSF as compared with CN [15]. Interestingly,
we found HGF was correlated with Ab1–42 levels in ADNI
but not in WUSTL. This maybe because CN subjects with
abnormal CSF Ab1–42 levels were excluded in our analysis
(Supplementary Fig. 1E).
Lp(a) protein (equivalent to LPA gene) consists of an low-
density lipoprotein-like particle. Studies showed that
increased plasma concentration of Lp(a) was associated
with cerebrovascular disease [39]. Besides, evidence sug-
gests that serum Lp(a) levels were highly correlated with
the severity of AD [40], in line with what was observed in
our cohorts (Supplementary Fig. 2B). However, it was not
reported in any of the previous CSF–based MAP-RBM
studies for diagnosis [14–16].
PRL is secreted by the pituitary gland and its elevated
concentration in serum correlates with abnormalities in im-
mune response [41]. The physiological importance of PRL is
not fully known, but some suggested it maybe a regulator of
stress response [42]. Same as Lp(a), PRL was not reported
previously [14–16]. Its level was slightly higher in subjects
with low Ab1–42 levels than the others (Supplementary
Fig. 1C).
RETN is a hormone likely associated with inflammation
[43] and atherosclerosis [44]. It was a reported AD
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higher levels of RETN in subjects with lower Ab1–42 levels
(Fig. 1B).
VEGF regulates vessel formation, axonal growth, and
neuronal loss [45]. Low plasma and CSF VEGF levels in
AD have been reported by other studies [38], previously in
WUSTL [15], and were observed in all our cohorts
(Fig. 1A). Findings from a recent study, however, suggest
that VEGF189 levels were higher in AD and were involved
in cognitive impairment via a role in neuroprotection and
neurogenesis [46]. The higher VEGF levels of AD maybe
due to the measurement of VEGF possessing a different
immunoglobulin-like domain.
In our study, we identified three proteins which may
reflect cognitive changes in the AD spectrum. PPP was
one of the diagnostic targets reported in previous studies in
both CSF and plasma [15,29]. Its levels were altered in
plasma clinical MCI/AD populations [47]. In our combined
cohort, we found CSF PPP levels to be statistically different
between samples with questionable and mild cognitive prob-
lems, suggesting this maybe a possible target for AD staging.
The roles for the other two proteins (IgA and TF) in AD
are relatively less investigated. IgA was shown to improve
the integrity of the blood-brain barrier (BBB) in rats [48].
The protective function of IgA to prevent breakdown of
the BBB could delay or prevent AD [49]. On the other
hand, TF may contribute to the formation of senile plaques,
but the mechanism is not clear [50].
To conclude, using CSF samples from three different co-
horts, we were able to identify robust analytes measured
from the MAP-RBM platform. Focusing on samples whose
cognitive status was consistent with their amyloid status,
seven analytes were found to be statistically correlated
with CSF Ab1–42 levels. These analytes contribute differ-
ently in AD pathophysiology, including inflammatory
response, lipid metabolism, atherosclerosis, and insulin
resistance. Moreover, VEGF was strongly associated with
cognitive impairment as measured by MMSE scores, fol-
lowed by PPP. Although IgA and TF are relatively unex-
plored, they may reflect cognitive changes in the
symptomatic AD samples. All these promising analytes
need to be validated in a better well-designed study to verify
their clinical utility.Acknowledgments
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1. Systematic review: We used a multianalyte platform
by Rules Based Medicine to uncover new protein an-
alytes that were suggestive of the presence or
absence of amyloid pathology quantified by cerebro-
spinal fluid (CSF) Ab1–42 levels (Ab1–42 cutoff
defined by Shaw et al. using Alzheimer’s Disease
Neuroimaging Initiative data) and study how these
biomarkers correlate with cognitive decline on symp-
tomatic Alzheimer’s disease subjects from three in-
dependent cohorts.
2. Interpretation: After adjusting for confounding ef-
fects, seven protein analytes (CD40 antigen fatty
acid binding protein, hepatocyte growth factor, lipo-
protein a, prolactin, resistin, and vascular endothelial
growth factor [VEGF]) were highly correlated with
abnormal CSFAb1–42 levels. VEGF, pancreatic poly-
peptide immunoglobulin A, and tissue factor / throm-
boplastin were associated with cognitive impairment
as measured by mini-mental state examination.
3. Future directions: Only some of the identified analy-
tes are known to be associated with AD physiopa-
thology. In the future, we will include mild
cognitive impairment subjects in our study. Further
investigation is also required to study the longitudi-
nal aspects of these analytes on subjects with
different rates of cognitive decline.References
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